Untitled
Introduction to Medicinal Chemistry
Presented by: Gebretekle G., B. Pharm., MSc in Medicinal Chemistry
Affiliation: Pharmaceutical Analysis Unit, Department of Pharmacy, College of Medicine and Health Sciences, Adigrat University
Objectives
Upon completion of this session, students will be able to:
- Define Medicinal Chemistry and understand its scope
- Describe the relationships between Medicinal Chemistry and other disciplines
- Identify the source and classification of drugs
- Practice drug nomenclature based on different nomenclature systems
- Understand methods for designing analogs
Introduction to Medicinal Chemistry
1) Definition of Medicinal Chemistry
- Medicinal Chemistry involves:
- Invention, discovery, identification, development, and interpretation of mechanisms of action of biologically active compounds at the molecular level.
- Design and synthesis of compounds as potential new drugs, often referred to as the generation of new chemical entities (NCEs) for medicinal purposes.
- Emphasizes the chemistry of receptors.
1.1) Impact of Chemical Structure
- It studies how the chemical structure and physicochemical properties of a molecule influence drug pharmacokinetics and pharmacological properties.
- Physicochemical properties: Influence of functional groups (FGs) on hydrophilicity, partitioning coefficient, stereochemistry, etc.
- Total concern for systematic modification of drug molecules to determine how changes affect biological activities.
- Structure Activity Relationships (SAR): Relation of structural features of molecules with biological activity.
1.2) Main Stages of Medicinal Chemistry
- Lead Discovery:
- New active drugs are identified and prepared from natural sources, chemical reactions, or biotechnological processes.
- Lead Optimization:
- Enhancing lead compounds to boost potency and selectivity while reducing toxicity.
- Drug Candidate Development:
- Optimization for bulk production, modification of pharmacokinetics and pharmaceutical properties for clinical use.
Related Disciplines in Medicinal Chemistry
- Key Fields:
- Organic Chemistry
- Combinatorial Chemistry
- Computational Chemistry
- Biochemistry
- Analytical Chemistry
- X-ray Crystallography
- NMR Spectroscopy
- Pharmacognosy
- Molecular Modelling
- Genomics & Proteomics
- Bioinformatics
- Immunology
- Molecular Biology
- Pharmacology
- Microbiology
- Medicinal Chemistry resides at the interface of chemistry and biology.
Combinatorial Chemistry
- Involves rapid synthesis of large collections of compounds, known as compound libraries.
- Accelerates the drug discovery process.
Computational Chemistry
- Utilizes mathematical methods in computers to produce information regarding various properties of molecules.
- X-ray Crystallography:
- Essential for studying crystal structures of target molecules, providing vital 3D structural parameters necessary for rational drug design.
Definition and Classification of Drugs
1.3) Definition of a Drug
- A drug is defined as a single chemical entity utilized for:
- Diagnosis
- Prevention
- Treatment of symptoms
- Cure of diseases
- Broader definition: "All chemicals other than food that affect living processes".
1.4) Classification of Drugs
- Based on Origin:
- Natural (plants, animals, minerals, microorganisms)
- Synthetic
- Semi-synthetic
- Based on Chemical Structure:
- Steroids, penicillins, quinolones, azoles, etc.
- Based on Pharmacological Action:
- Antivirals, antianginals, diuretics, bronchodilators, antibacterials.
- Based on Site of Action:
- CNS drugs, CVS drugs, GIT drugs, chemotherapeutic agents, etc.
1.5) Nomenclature of Drugs
- Code Number/Name:
- Assigned by manufacturers before an approved name is coined (e.g., RO15-1788 later became flumazenil).
- Chemical Name:
- May not be suitable for clinical use, e.g., N-acetyl-p-aminophenol for paracetamol.
- Proprietary/Brand/Trade Name:
- Chosen by the pharmaceutical company; one drug may have several proprietary names (e.g., atenolol has names like Atecort, Aten, Betacard).
- Non-Proprietary/Generic/Official Name:
- The approved official name in pharmacopeia, e.g., paracetamol or acetaminophen.
1.6) Sources of Drugs
- Natural Sources (e.g., from animals for insulin):
- Animal (8.7%): Insulin, gonadotropins, thyroid extracts.
- Mineral (9.1%): Calcium, potassium, phosphorus, sodium, magnesium, iron.
- Plant (11.1%): Vincristine, taxol, digoxin, quinine, reserpine.
- Microorganisms: Antibiotics such as penicillin, streptomycin, tetracycline.
- Synthetic Sources (48.9%):
- Widely used for cost efficiency and efficacy (e.g., aspirin, paracetamol).
- Semi-Synthetic Sources (9.5%):
- Recombinant DNA technology (e.g., insulin).
- Biosynthetic:
- Drugs that are complex polypeptides, difficult and costly to synthesize in a lab (e.g., erythropoietin, hepatitis vaccine).
Receptors and Drug Action
1.7) Understanding Receptors
- A receptor is a specific chemical component of the cell that interacts with a drug to create pharmacological effects.
- Receptors include proteins, glycoproteins (e.g., G-protein coupled receptors), and sometimes nucleic acids.
Types of Receptors
I) Ligand-Gated Ion Channels
- Membrane-bound receptors directly linked to ion channels composed of five protein subunits that traverse the membrane four times.
- Agonists open the channel causing depolarization or hyperpolarization, with response time measured in milliseconds.
- Examples include nicotine, glutamate, GABA-A, and 5-HT3 receptors.
II) G-Protein Coupled Receptors (GPCRs)/Metabotropic Receptors
- Contains binding sites for neurotransmitters (extracellularly) and G-protein.
- Ligand binding alters receptor shape, opening a binding site for G-proteins; the G-protein fragments then interact with enzymes to propagate the signal.
- Significant as 30% of drugs act via these receptors (e.g., muscarinic, histaminic, adrenergic, dopaminergic receptors).
III) Tyrosine Kinase-Linked Receptors
- Membrane-bound receptors with:
- Extracellular domains that bind ligands at the N-terminus.
- Intracellular domains with enzymatic functions (tyrosine kinase activity at the C-terminus).
- Ligand binding activates the receptor causing phosphorylation of tyrosine residues.
- Examples include receptors for insulin and various cytokines.
IV) Intracellular/Nuclear Receptors
- Located in the cytosol; require hydrophobic ligands that can cross membranes.
- Activated receptors translocate to the nucleus to initiate gene transcription, operating over hours to days—slower than other receptors.
- Zinc ions stabilize the DNA binding region.
- Examples include receptors for steroid hormones, thyroid hormones, vitamin D, and retinoid.
Drug-Receptor Interactions
Covalent Interactions
- Formed when a drug atom and receptor atom share a pair of electrons, resulting in essentially irreversible engagement under biological conditions.
- Rare under non-toxic conditions due to the reversible nature of most interactions.
- Example: Bond formed between phenoxybenzamine and its receptor.
Ionic Interactions
- Driven by attraction between oppositely charged receptor sites and ionized drug groups, representing strong electrostatic interactions.
- More common than covalent interactions, especially between charged ionic molecules.
- Receptors with ionizable groups at physiological pH interact with ionized drugs (e.g., acetylcholine).
Hydrogen Bonding
- Created when hydrogen bonded to an electronegative atom possesses a positive charge and is attracted to another atom with a relative negative charge.
- Critical for hydrophilicity; many hydrogen bonds grant stability to drug-receptor interactions.
Van der Waals Attractions
- The weakest intermolecular forces occurring between nonpolar groups, which are highly distance and temperature-dependent.
Hydrophobic Interactions
- Result from interactions between nonpolar drug and receptor groups, with the interaction generally being weak but significant for molecular functions.
- Notable in interactions between lipophilic drugs and lipid components of membranes or with nonpolar receptor regions.
1.8) Drug Design
- The drug discovery process begins with identifying hits, which are substances with preferential activity for a target, characterized by:
- Reproducible activity in relevant bioassays.
- Confirmed structure and high purity.
- Target specificity and novelty.
- Chemically tractable structure.
Hit Validation Criteria
- Must be active in vivo (in tissue), have no major human toxicity, lack chemically reactive functions, provide patent potential, and present analogs that illustrate clear SARs.
- Conversion of hits to leads is termed Hits-to-Leads (H2L) or lead generation.
Lead Compounds
- A lead compound is recognized for its strong potential to transition into drug development, characterized by satisfactory properties (potency, selectivity, PK, physicochemical properties, novelty, and low toxicity).
- The optimization of lead compounds is grounded in SAR insights to enhance affinity, geometry, and stability.
Sources of Lead Compounds
I) Screening of Natural Products
- Early chemists searched for new medicines through plant sources with pharmacological actions.
- Natural source examples include papaver somniferum and erythroxylon coca.
II) Random Screening of Synthetic Organic Compounds
- Introduced in the 1930s after sulphonamides' discovery, which involved testing vast libraries of chemicals (often up to 500,000 compounds for a single activity).
- Amantadine as an anti-influenza-A drug originated from broad antiviral screening, though this method is seen as inefficient.
- High-throughput screening (HTS) systems enhance efficiency by using robotics and combinatorial chemistry.
III) Rational Approach
- Based on knowledge of the drug target, where understanding geometry and chemistry of the active site leads to compound design (e.g., Captopril).
- Steps include identifying disease, target, bioassay, and lead optimization, ultimately leading to preclinical studies and clinical trials.
IV) Enhancing Side Effects of Existing Drugs
- Initial development of phenothiazine antipsychotics stemmed from improving antihistamine properties.
- Notable drugs transitioned from sedative agents to antipsychotics (e.g., promethazine to chlorpromazine).
V) Serendipity
- Accidental discovery cases include penicillin from contaminated Staphylococcus cultures or phenylbutazone's original function as a solubilizer for aminopyrine.
VI) Drug Metabolite as Leads
- Metabolites like acetaminophen can serve as new drug leads. They may also exhibit better profiles in terms of absorption, action duration, and reduced toxicity.
VII) Analog Designing
- Aim to create new drugs with improved properties over prototypes.
- Analog drugs are termed “me-too drugs,” retaining similarities with prototypes in chemical and pharmacological aspects.
- Example: Simvastatin is a me-too drug more effective than its prototype, lovastatin.
Molecular Design Considerations
I) Branching
- Can affect lipophilicity due to hydrogen bonding stability and could significantly alter pharmacological activity if hydrocarbons are critical for receptor interactions.
- Example: Differences in activity between promethazine (H1-blocker) and promazine (antipsychotic) mainly hinge on their alkyl amine side chains.
II) Rigidification
- Complexifying a drug molecule prevents additional conformations, potentially enhancing receptor fit and activity.
- Example: Etorphine, a rigidified morphine derivative, shows significantly higher potency and affinity for analgesic receptors.
III) Ring Expansion or Contraction
- Altering ring sizes can shift binding groups' relative positions, potentially improving receptor interactions.
IV) Ring Variations
- Creating selective β-blockers through aromatic ring substitution improves receptor binding efficiency.
Molecular Manipulation Techniques
I) Molecular Addition
- Involves associating different moieties via weak forces such as electrostatic attraction and hydrogen bonding.
II) Molecular Simplification
- Involves removing non-essential structural parts while retaining activity to create simpler, more synthesize-friendly compounds.
- Example: Procaine derived from cocaine; morphine has undergone simplification for analog generation with fewer side effects.
III) Molecular Replication
- Involves associating identical moieties through covalent bonding.
IV) Molecular Hybridization
- Similar to replication but involves different moieties combined through covalent bonds.
Special Processes
- Alterations to increase or decrease a molecule’s dimension or flexibility:
- Ring closure (e.g., Nefopam) versus ring opening (e.g., Diethylstilbesterol).
V) Homologation
- Adjusting structure through incremental changes (e.g., methyl to ethyl) may modulate agonist or antagonist qualities.
VI) Introduction of Double Bonds
- Can lead to geometric isomer formations with differing biological activities and alteration of physicochemical properties.
VII) Chiral Modification
- Changes to stereochemistry can dramatically influence pharmacological activity (e.g., ephedrine vs. pseudoephedrine).
VIII) Introduction/Removal of Bulky Groups
- Altering bulky groups affects physical and chemical properties significantly impacting drug efficacy.
IX) Group Replacement and Bioisosterism
- Alteration of chemical properties will employ isosteric replacement leading to the identification of bioisosters with similar biological activities.
Drug Discovery Process Overview
- FDA Approved Drugs: 1
- Clinical Trials: 250 compounds
- Preclinical Studies: 10,000 compounds
- Drug Discovery: This sequence indicates that the number of compounds at each developmental step decreases as the process narrows down.
Conclusion: Stereochemistry and Drug Action
- The study of three-dimensional molecular structures, essential for specific enzyme-substrate interactions, affecting both metabolism and pharmacological outcomes.
- Isomers:
- Same molecular formula but differ in atom arrangements, leading to different properties.
Classification of Isomers
- Constitutional Isomers: Same atom connectivity but differ in structural arrangement.
- Stereoisomers: Characterized by different spatial arrangements.
- Enantiomers: Chiral and optically active; properties differ significantly (e.g., dextromethorphan vs. levomethorphan).
- Diacetyl Isomers: Can exist as non-mirror images (diastereomers) when chiral centers are present.
The End
Note: This document encompasses comprehensive details from the session on Medicinal Chemistry to ensure a deep understanding and facilitate effective study.